Honz Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

De CEO Honz Pharmaceutical is Jiangtao Hong, benoemd in Dec2019, heeft een ambtstermijn van 4.92 jaar. bezit rechtstreeks 0.51% van de aandelen van het bedrijf, ter waarde CN¥ 11.98M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.9 jaar en 1.9 jaar.

Belangrijke informatie

Jiangtao Hong

Algemeen directeur

CN¥411.9k

Totale compensatie

Percentage CEO-salaris	n/a
Dienstverband CEO	4.9yrs
Eigendom CEO	0.5%
Management gemiddelde ambtstermijn	4.9yrs
Gemiddelde ambtstermijn bestuur	1.9yrs

Recente managementupdates

Recent updates

Honz Pharmaceutical Co., Ltd.'s (SZSE:300086) Shares Climb 31% But Its Business Is Yet to Catch Up

Sep 30

CEO

Jiangtao Hong (54 yo)

4.9yrs

Tenure

CN¥411,900

Compensatie

Mr. Jiangtao Hong has been President at Honz Pharmaceutical Co., Ltd. since December 19, 2019 and served as its Vice President.

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jiangyou Hong	Chairman & Financial Director	16.9yrs	CN¥542.00k	1.69% CN¥ 39.8m
Jiangtao Hong	President	4.9yrs	CN¥411.90k	0.51% CN¥ 12.0m
Liping Hong	Vice Chairman & VP	16.9yrs	CN¥425.70k	0.17% CN¥ 4.0m
Dexin Lin	VP & Board Secretary	12.8yrs	CN¥374.50k	geen gegevens
Yong Wang	Assistant to the Chairman	no data	CN¥324.00k	geen gegevens
Yong Zhou	Accounting Supervisor	no data	geen gegevens	geen gegevens

4.9yrs

Gemiddelde duur

54yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van 300086 wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jiangyou Hong	Chairman & Financial Director	16.9yrs	CN¥542.00k	1.69% CN¥ 39.8m
Liping Hong	Vice Chairman & VP	16.9yrs	CN¥425.70k	0.17% CN¥ 4.0m
Qinghe Wu	Independent Director	1.9yrs	CN¥90.00k	geen gegevens
Huan Xue Zheng	Independent Director	1.9yrs	CN¥90.00k	geen gegevens
Youquan Li	Non-Independent Director	4.9yrs	CN¥180.00k	geen gegevens
Dongxiong Hong	Director	1.9yrs	CN¥138.90k	geen gegevens
Chunying Wang	Non-Employee Supervisor	4.9yrs	geen gegevens	0.00011% CN¥ 2.6k
Jicheng Zhang	Independent Director	4.9yrs	CN¥90.00k	geen gegevens
Mengke Sun	Non-Employee Supervisor	1.9yrs	geen gegevens	geen gegevens
Zhihui Hong	Non-Independent Director	less than a year	geen gegevens	geen gegevens
Canhui Fang	Independent Director	less than a year	geen gegevens	geen gegevens

1.9yrs

Gemiddelde duur

55yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van 300086 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.9 jaar), wat duidt op een nieuw bestuur.

Honz Pharmaceutical Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

High number of new directors

Honz Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Honz Pharmaceutical Co., Ltd. Announces Directorate Appointments

High number of new and inexperienced directors

Honz Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

High number of new and inexperienced directors

Recent updates

Third quarter 2024 earnings released: CN¥0.047 loss per share (vs CN¥0.082 loss in 3Q 2023)

Honz Pharmaceutical Co., Ltd.'s (SZSE:300086) Shares Climb 31% But Its Business Is Yet to Catch Up

Honz Pharmaceutical Co., Ltd. to Report Q3, 2024 Results on Oct 30, 2024

New minor risk - Share price stability

Second quarter 2024 earnings released: CN¥0.12 loss per share (vs CN¥0.002 profit in 2Q 2023)

High number of new directors

Honz Pharmaceutical Co., Ltd. to Report First Half, 2024 Results on Aug 27, 2024

First quarter 2024 earnings released: CN¥0.10 loss per share (vs CN¥0.034 profit in 1Q 2023)

Honz Pharmaceutical Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

New minor risk - Share price stability

Honz Pharmaceutical Co., Ltd. to Report Fiscal Year 2023 Results on Apr 23, 2024

Third quarter 2023 earnings released: CN¥0.082 loss per share (vs CN¥0.049 loss in 3Q 2022)

Second quarter 2023 earnings released: EPS: CN¥0.002 (vs CN¥0.092 loss in 2Q 2022)

Honz Pharmaceutical Co., Ltd., Annual General Meeting, Jun 29, 2023

Full year 2022 earnings released: CN¥0.42 loss per share (vs CN¥0.024 profit in FY 2021)

Honz Pharmaceutical Co., Ltd. Announces Directorate Appointments

High number of new and inexperienced directors

Third quarter 2022 earnings released: CN¥0.049 loss per share (vs CN¥0.036 profit in 3Q 2021)

Second quarter 2022 earnings released: CN¥0.092 loss per share (vs CN¥0.062 loss in 2Q 2021)

Honz Pharmaceutical Co., Ltd., Annual General Meeting, Jun 30, 2022

First quarter 2022 earnings released: CN¥0.10 loss per share (vs CN¥0.066 loss in 1Q 2021)

High number of new and inexperienced directors

Full year 2021 earnings released: EPS: CN¥0.024 (vs CN¥0.021 in FY 2020)

Third quarter 2021 earnings released: EPS CN¥0.036 (vs CN¥0.012 loss in 3Q 2020)

Second quarter 2021 earnings released: CN¥0.062 loss per share (vs CN¥0.042 profit in 2Q 2020)

Honz Pharmaceutical Co., Ltd. Announces Final Profit Distribution Proposal for 2020

Full year 2020 earnings released: EPS CN¥0.021 (vs CN¥0.059 loss in FY 2019)

New 90-day low: CN¥4.85

New 90-day low: CN¥5.87

New 90-day low: CN¥6.07

New 90-day low: CN¥6.38

Honz Pharmaceutical Co., Ltd. announced that it expects to receive CNY 634.6 million in funding

Third quarter earnings released

Earnings released

Honz Pharmaceutical Co., Ltd. to Report First Half, 2020 Results on Aug 25, 2020

New 90-day high - CN¥8.26

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd